Satellos Bioscience Inc. , a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management.
The drug target for the Duchenne program is AAK1, a protein kinase in the Notch pathway, which the Company discovered can be modulated to enable muscle…
Satellos Bioscience Inc. , a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management.
Satellos Bioscience Inc. , a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management.
Satellos Bioscience Inc : Satellos Expands Leadership Team with New CFO Appointment finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.